Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : STC3141
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Grand Pharma’s STC3141 Meets Phase II Endpoint in China for First Time
Details : STC3141 is the first investigational sepsis treatment program is centered on rebuilding immune homeostasis.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 07, 2025
Lead Product(s) : STC3141
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban Hydrochloride Monohydrate
Therapeutic Area : Neurology
Study Phase : Phase IV
Recipient : Beijing Tiantan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Study on Tirofiban With Aspirin in the Treatment of Acute Penetrating Artery Territory Infarction
Details : Tirofiban HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Branch Atheromatous Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 05, 2022
Lead Product(s) : Tirofiban Hydrochloride Monohydrate
Therapeutic Area : Neurology
Highest Development Status : Phase IV
Recipient : Beijing Tiantan Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Tirofiban is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Ischemic Stroke.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 12, 2022
Lead Product(s) : Tirofiban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable